A phase I single-blind randomised placebo controlled dose escalating study of one virosome formulated CD4 and two virosomes formulated CD8 hepatitis C virus (HCV) vaccine components (PEV2A and PEV2B) administered to healthy adult volunteers.

Trial Profile

A phase I single-blind randomised placebo controlled dose escalating study of one virosome formulated CD4 and two virosomes formulated CD8 hepatitis C virus (HCV) vaccine components (PEV2A and PEV2B) administered to healthy adult volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2010

At a glance

  • Drugs Hepatitis C vaccine (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 16 Feb 2010 Actual end date added to 1 Jun 2008 as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2008 Status changed from recruiting to in progress, according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top